2-chloro-N-(3-ethynylphenyl)-6,7-dimethoxy-N-methyl quinazoline-4-amine | 1403933-70-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-chloro-N-(3-ethynylphenyl)-6,7-dimethoxy-N-methyl quinazoline-4-amine
• 英文别名: 2-chloro-N-(3-ethynylphenyl)-6,7-dimethoxy-N-methylquinazolin-4-amine
• CAS: 1403933-70-9
• 化学式: C₁₉H₁₆ClN₃O₂
• 分子量: 353.808
• InChiKey: URKOQORBHPOFSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  47.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,4-二氯-6,7-二甲氧基喹唑啉 在 盐酸 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 、 mineral oil 为溶剂， 反应 4.0h， 生成 2-chloro-N-(3-ethynylphenyl)-6,7-dimethoxy-N-methyl quinazoline-4-amine
  参考文献：
  名称：

  ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS

  摘要：

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。

  公开号：

  US20140080848A1

文献信息

• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS
  申请人：National Taiwan University

  公开号：US20140080848A1

  公开（公告）日：2014-03-20

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.

  基于厄洛替尼（一种EGFR抑制剂）骨架合成了一系列单取代和双取代的喹唑啉和嘧啶衍生物，并评估了它们对肝细胞癌和人类肺腺癌的生物活性。
• ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANCER DRUGS
  申请人：National Yang-Ming University

  公开号：US20150246891A1

  公开（公告）日：2015-09-03

  A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
• US9394261B2
  申请人：——

  公开号：US9394261B2

  公开（公告）日：2016-07-19
• Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity
  作者：Kuen-Feng Chen、Kuan-Chuan Pao、Jung-Chen Su、Yi-Chieh Chou、Chun-Yu Liu、Hui-Ju Chen、Jui-Wen Huang、InKi Kim、Chung-Wai Shiau

  DOI：10.1016/j.bmc.2012.08.039

  日期：2012.10

  Cancerous inhibitor of PP2A (CIP2A) is a novel human oncoprotein that inhibits PP2A, contributing to tumor aggressiveness in various cancers. Several studies have shown that downregulation of CIP2A by small molecules reduces PP2A-dependent phosphorylation of Akt and induces cell death. Here, a series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma were evaluated. The di-substituted quinazoline and pyrimidine derivatives were more potent inhibitors of cancer-cell proliferation than the mono-substituted derivatives. In particular, compound 1 with chloride at position 2 of quinazoline was as potent as erlotinib in inducing cell death but no inhibition for EGFR activity. Further assays confirmed a correlation between cell death, and CIP2A and Akt inhibition by these derivatives. Among all the derivatives, compounds 19 and 22 showed the most potent antiproliferative activities and the strongest inhibition of CIP2A and p-Akt expression. (C) 2012 Elsevier Ltd. All rights reserved.